Stable Id Screen title Pubmed Id Entrez Id Author-provided gene Id Assay Biomodel Reagent Id Score type Score cutoff Score Phenotype Comment GR00184-A-1 Self-renewal and pluripotency in human embryonic stem cells (1) 20953172 995 NM_001790 POU5F1 protein expression hESC H1 M-003228-01 Z-score < -2 -0.569407665163013 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 3987 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean -37.65 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 3987 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean -74.91 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 121334 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean 32.14 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 121334 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean 86.04 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 121335 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean 86.84 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 121335 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean 44.71 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 121336 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean -58.04 none GR00149-A-1 Ciliogenesis and cilium length (1) 20393563 995 995 Smoothed protein expression htRPE 121336 Normalized percent inhibition > 1.5 OR < -1.5 standard deviations from mean 47.02 none GR00133-A-1 Salmonella enterica subspecies 1 serovar Typhimurium invasion (1) 21407211 995 995 Gentamycin protection invasion assay HeLa np log2 median Complex criteria -0.223062 none GR00151-A-1 Homologous recombination DNA double-strand break repair (HR-DSBR) (1) 20613862 995 ENSG00000158402 (HR-DSBR) DR-GFP reporter HeLa np Z-score < -2 OR > 2 0.401 none GR00180-A-1 Hepatitis C virus replication (1) 19286138 995 995 HCV replicon RNA copy number Huh7/Rep-Feo PL-50015 q-value Complex criteria 0.744 none GR00054-A Combinatorial effect with paclitaxel 17429401 995 NM_001790 Viability (synthetic lethal) NCI-H1155 np Paclitaxel/control ratio Complex criteria 0.895 none GR00199-A-2 NF-kappaB pathway regulation (2) 22308454 995 995 NF-kappaB pathway reporter HEK293 D-003228-05,D-003228-06,D-003228-07,D-003228-08 Complex, sp Complex criteria sp Downregulation of NF-kappaB pathway after TNFalpha stimulation TNFalpha stimulation GR00199-A-2 NF-kappaB pathway regulation (2) 22308454 995 995 NF-kappaB pathway reporter HEK293 D-003228-05,D-003228-06,D-003228-07,D-003228-08 Complex, sp Complex criteria sp Downregulation of NF-kappaB pathway after IL-1beta stimulation IL-1beta stimulation GR00199-A-1 NF-kappaB pathway regulation (1) 22308454 995 995 NF-kappaB pathway reporter HEK293 D-003228-05,D-003228-06,D-003228-07,D-003228-08 Complex, sp Complex criteria sp Downregulation of NF-kappaB pathway after LMP1 stimulation decreased viability (< 50 %) for D-003228-05 GR00204-A-2 RTK/Ras pathway regulation (2) 19922411 995 NM_001790,NM_022809 Akt phosphorylation A549 np Percentage Top 20 12.26 none pooled siRNAs GR00204-A-1 RTK/Ras pathway regulation (1) 19922411 995 NM_001790,NM_022809 Erk phosphorylation A549 np Percentage Top 20 3.253 none pooled siRNAs GR00205-A Mitotic exit regulation 20711181 995 995 H2B and IBB protein expression HeLa SI02627079,SI02658642,SI02658649 Z-score > 3 np none GR00210-A Focal adhesion formation 19667130 995 995 paxillin protein expression HeLa np Z-score > 3.5 OR < -3.5 sp Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance, decreased cell spreading clusters: MC1, DC2, CC8 GR00056-A Melanogenesis 19057677 995 NM_001790 Melanin protein expression and viability MNT-1 np Normalized absorbance ratio > 2 standard deviations below mean 0.86 none GR00098-A-1 Cell division (1) 17994010 995 ENSG00000158402 Cell number and DNA content HeLa ENSG00000158402 Complex, sp Complex criteria sp none GR00197-A-1 Human papillomavirus oncogene expression regulation (1) 20133580 995 995 HPV18 LCR reporter activity C33A/BE2/18LCR c4 M-003228-01 Z-score >= 2 0.237932538 none GR00016-A Wnt/beta-catenin pathway regulation 19471023 995 995 Wnt/beta-catenin pathway reporter RKO np Z-score > 2 1.64 none GR00053-A Genome stability 19647519 995 NM_001790 gamma-H2AX phosphorylation and DNA content HeLa np p-value Complex criteria sp none GR00228-A TNF-induced apoptosis 20460151 995 NM_022809 Viability (synthetic lethal) HeLa np Death index 99% confidence interval: > 2.58 SD; 95% confidence interval: > 1.96 SD 1.639597 none GR00055-A-3 Epithelial cell migration (3) 19160483 995 995 Cell migration and viability MCF-10A overexpressing ERBB2 np Area score and Alamar score Complex criteria np Decreased viability GR00055-A-2 Epithelial cell migration (2) 19160483 995 995 Cell migration and viability MCF-10A overexpressing BCL2 np Area score and Alamar score Complex criteria np Decreased viability GR00055-A-1 Epithelial cell migration (1) 19160483 995 995 Cell migration and viability MCF-10A np Area score and Alamar score Complex criteria np Decreased viability deconvoluted validated siRNAs: 1/2 GR00231-A Cell proliferation 21765947 995 NM_001790 Viability HeLa M-003228-01 Z-score < -1.96 OR > 1.96 -0.077 none GR00232-A-1 DNA damage regulation after ionizing radiation (1) 20810650 995 NM_022809 Ionizing radiation sensitivity U2OS v2HS_116126 log2 mean ratio < -1 OR > 1 2.074066617 Decreased ionizing radiation sensitivity GR00236-A-1 Homologous recombination DNA double-strand break repair (HR-DSBR) (1) 22344029 995 995 (HR-DSBR) DR-GFP reporter and DNA content DR-U2OS M-003228-01 Relative HR ratio < ~0.4 OR > 1.88 1.3126464010827 none GR00240-S-1 TRAIL-induced apoptosis (1) 24442637 995 NM_001790 Viability U251MG M-003228-01 Z-score > 4 0.55 none GR00240-S-2 TRAIL-induced apoptosis (2) 24442637 995 NM_001790 Viability (synthetic lethal) U251MG M-003228-01 Differential score > 3.6 AND viability Z-score < 4 -0.32 none Z-score 0.2785 GR00242-A-1 Selective autophagy regulation (1) 22020285 995 NM_001790 Sindbis virus (SIN) capsid SIN-mCherry.capsid and autophagosome GFP–LC3 protein expression HeLa/GFP-LC3 np Z-score Complex criteria sp none GR00247-A-1 Regulation of FOXO1 nuclear localization (1) 21460183 995 EGFP-FOXO1a protein expression and DNA content U2OS np Complex, sp Complex criteria sp none rank: 15458 GR00249-S Vaccinia virus (VACV) infection 23401514 995 995 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa J-003228-09 Z-score >= 1 OR <= -1.5 1.66123 Increased vaccinia virus (VACV) infection number of cells compared to control (%): 92.21 GR00249-S Vaccinia virus (VACV) infection 23401514 995 995 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa M-003228-02 Z-score >= 1 OR <= -1.5 -1.65959 Decreased viability number of cells compared to control (%): 38.34 GR00249-S Vaccinia virus (VACV) infection 23401514 995 995 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa s2756 Z-score >= 1 OR <= -1.5 -2.13358 Decreased vaccinia virus (VACV) infection number of cells compared to control (%): 65.15 GR00249-S Vaccinia virus (VACV) infection 23401514 995 995 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa s2757 Z-score >= 1 OR <= -1.5 0.02328 none number of cells compared to control (%): 61.49 GR00249-S Vaccinia virus (VACV) infection 23401514 995 995 Vaccinia virus VACV IHD-J/GFP protein expression and DNA content HeLa s2758 Z-score >= 1 OR <= -1.5 -1.25012 none number of cells compared to control (%): 70.11 GR00250-A-2 Combinatorial effect with MLN4924, a NAE inhibitor (2) 23100467 995 995 Viability (synthetic lethal) A375 D-003228-07 Complex, sp Complex criteria sp none duplicate screen GR00250-A-2 Combinatorial effect with MLN4924, a NAE inhibitor (2) 23100467 995 995 Viability (synthetic lethal) A375 D-003228-07 Complex, sp Complex criteria sp Increased viability with MLN4924 (a NAE inhibitor) sextuplicate screen GR00250-A-2 Combinatorial effect with MLN4924, a NAE inhibitor (2) 23100467 995 995 Viability (synthetic lethal) A375 D-003228-05 Complex, sp Complex criteria sp Synthetic lethal with MLN4924 (a NAE inhibitor) duplicate screen, sextuplicate screen GR00250-A-2 Combinatorial effect with MLN4924, a NAE inhibitor (2) 23100467 995 995 Viability (synthetic lethal) A375 D-003228-06 Complex, sp Complex criteria sp Increased viability with MLN4924 (a NAE inhibitor) duplicate screen, sextuplicate screen GR00250-A-2 Combinatorial effect with MLN4924, a NAE inhibitor (2) 23100467 995 995 Viability (synthetic lethal) A375 D-003228-08 Complex, sp Complex criteria sp Synthetic lethal with MLN4924 (a NAE inhibitor) duplicate screen, sextuplicate screen GR00250-A-3 Combinatorial effect with MLN4924, a NAE inhibitor (3) 23100467 995 995 Viability (synthetic lethal) HCT116 D-003228-05 Complex, sp Complex criteria sp none 91 nM MLN4924; set: 320DDR; final hit GR00250-A-3 Combinatorial effect with MLN4924, a NAE inhibitor (3) 23100467 995 995 Viability (synthetic lethal) HCT116 D-003228-06 Complex, sp Complex criteria sp Increased viability with MLN4924 (a NAE inhibitor) 91 nM MLN4924; set: 320DDR; final hit GR00250-A-3 Combinatorial effect with MLN4924, a NAE inhibitor (3) 23100467 995 995 Viability (synthetic lethal) HCT116 D-003228-07 Complex, sp Complex criteria sp Synthetic lethal with MLN4924 (a NAE inhibitor) 91 nM MLN4924; set: 320DDR; final hit GR00250-A-3 Combinatorial effect with MLN4924, a NAE inhibitor (3) 23100467 995 995 Viability (synthetic lethal) HCT116 D-003228-08 Complex, sp Complex criteria sp Increased viability with MLN4924 (a NAE inhibitor) 91 nM MLN4924; set: 320DDR; final hit GR00252-A-1 Oncolytic Maraba rhabdovirus infection (1) 22014571 995 995 Viability OVCAR-8 np Composite MAD np -3.8659 Decreased viability after Maraba virus infection GR00252-A-2 Oncolytic Maraba rhabdovirus infection (2) 22014571 995 995 Viability U373 np Composite MAD np -2.9559 Decreased viability after Maraba virus infection GR00252-A-3 Oncolytic Maraba rhabdovirus infection (3) 22014571 995 995 Viability NCI-H226 np Composite MAD np -1.8826 Decreased viability after Maraba virus infection GR00253-A hepcidin regulation 24385536 995 NM_001790 hepcidin::fluc mRNA expression Huh7 np Z-score >= 1.755 OR <= -1.389 -0.301 none GR00255-A-1 Negative genetic interactions (1) 24104479 995 995 shRNA abundance HCT116 TRCN0000002432,TRCN0000002433,TRCN0000002434,TRCN0000002435 differential Gene Activity Ranking Profile (dGARP) < -1.0 0.754240206 none GR00255-A-2 Negative genetic interactions (2) 24104479 995 995 shRNA abundance HCT116 TRCN0000002432,TRCN0000002433,TRCN0000002434,TRCN0000002435 differential Gene Activity Ranking Profile (dGARP) < -1.0 0.38323286 none GR00255-A-3 Negative genetic interactions (3) 24104479 995 995 shRNA abundance HCT116 TRCN0000002432,TRCN0000002433,TRCN0000002434,TRCN0000002435 differential Gene Activity Ranking Profile (dGARP) < -1.2 0.911285291 none GR00255-A-4 Negative genetic interactions (4) 24104479 995 995 shRNA abundance HCT116 TRCN0000002432,TRCN0000002433,TRCN0000002434,TRCN0000002435 differential Gene Activity Ranking Profile (dGARP) < -1.2 0.502433906 none GR00255-A-5 Negative genetic interactions (5) 24104479 995 995 shRNA abundance HCT116 TRCN0000002432,TRCN0000002433,TRCN0000002434,TRCN0000002435 differential Gene Activity Ranking Profile (dGARP) < -0.8 -1.052515026 Negative genetic interaction between KRASG13D/+ and KRAS+/- GR00250-A-1 Combinatorial effect with MLN4924, a NAE inhibitor (1) 23100467 995 995 Viability (synthetic lethal) A375 M-003228-01 Complex, sp Complex criteria sp Synthetic lethal with MLN4924 (a NAE inhibitor) duplicate screen, sextuplicate screen GR00057-A-1 Wnt/beta-catenin pathway regulation (1) 18621708 995 NM_001790 Wnt pathway reporter HeLa M-003228-01 Z-score > 4 -0.74 none GR00057-A-2 Wnt/beta-catenin pathway regulation (2) 18621708 995 NM_001790 Wnt pathway reporter HeLa M-003228-01 Complex, SP Complex criteria sp none GR00293-A Combinatorial effect with paclitaxel 24860162 995 Viability HCC366 np Z-score < -2.5 0.114 none GR00300-A Combinatorial effect with RAF inhibitor PLX4720 23288408 995 shRNA abundance A375 TRCN0000002432,TRCN0000002433,TRCN0000002434,TRCN0000002435 Number of shRNAs ranked Top1000 > 2 0 none GR00303-A Clear cell renal cell carcinoma (ccRCC) survival regulation 22362593 995 NM_001790 Proliferation and Viability VHL-deficient RCC4 np Z-score <= -3 0.18 none GR00310-A-1 Sindbis virus (SINV) infection (1) 24367265 995 995 Sindbis virus (SINV) reporter U2OS np Z-score < -3 OR > 2 0.43 none GR00312-A NOD2 pathway regulation 23322906 995 995 NF-kappaB reporter HEK 293 np Normalized percent inhibition < -20 OR > 60; Inconclusive: < -20 and > 120 % viability OR > 60 and < 70 % viability 69.5 Decreased NF-kappaB reporter expression 71,9% viability GR00313-A TNF-alpha pathway regulation 22733992 995 NM_001790,NM_022809 NFkappaB pathway reporter HEK293T np Z-score <= -2.5 plus additional filters -1.31 none GR00318-A Huntingtin toxicity 23209424 995 995 Caspase 3/7 activity HEK293T np Sum of normalized caspase 3/7 activity mean and standard error < 0.683 1.061 none siRNA set: druggable genome GR00327-A Tumor formation 24292671 995 995 shRNA abundance SUM-149 CLL-H-009873 Z-score > 2.24 0.7529025037890855 none GR00327-A Tumor formation 24292671 995 995 shRNA abundance SUM-149 CLL-H-009870 Z-score > 2.24 1.5082410707700245 none GR00327-A Tumor formation 24292671 995 995 shRNA abundance SUM-149 CLL-H-009871 Z-score > 2.24 -0.21879234398958572 none GR00327-A Tumor formation 24292671 995 995 shRNA abundance SUM-149 CLL-H-009875 Z-score > 2.24 -0.05422288569217269 none GR00327-A Tumor formation 24292671 995 995 shRNA abundance SUM-149 CLL-H-009872 Z-score > 2.24 -0.6260598935648692 none GR00327-A Tumor formation 24292671 995 995 shRNA abundance SUM-149 CLL-H-009874 Z-score > 2.24 -0.07100853969350501 none GR00095-A p53 pathway components 15042092 995 NM_001790 Proliferation BJ-TERT-tsLT fibroblasts np np np np none GR00343-S Lentiviral shRNA "Achilles Heel" screen 26058080 995 995 shRNA abundance K562 TRCN0000002434 Log2 ratio <= -2 (shRNA abundance <= 25%) -0.5225000000000026 none GR00343-S Lentiviral shRNA "Achilles Heel" screen 26058080 995 995 shRNA abundance K562 TRCN0000002435 Log2 ratio <= -2 (shRNA abundance <= 25%) 1.0324999999999989 none GR00343-S Lentiviral shRNA "Achilles Heel" screen 26058080 995 995 shRNA abundance K562 TRCN0000002432 Log2 ratio <= -2 (shRNA abundance <= 25%) 0.14000000000000057 none GR00343-S Lentiviral shRNA "Achilles Heel" screen 26058080 995 995 shRNA abundance K562 TRCN0000002433 Log2 ratio <= -2 (shRNA abundance <= 25%) 0.4399999999999995 none GR00123-A Combinatorial effect with nutlin-3 16474381 995 NM_001790 Viability MCF-7 122601,122602,122603 log2 ratio np np none GR00351-A-1 Orthopoxvirus infection (1) 24516381 995 Vaccinia virus (VACV-A4L) infection A549 np Number of replicates in which second best hairpin scored among Top 500 > 0 1 Resistant to vaccinia virus (VACV-A4L) infection GR00363-A Endocytosis regulation 20190736 995 995 Transferrin (TF) and epidermal growth factor (EGF) subcellular localisation, DNA content HeLa SI02658642,SI02627086,SI02627079,SI02658649,esi9941,121334,121335,121336 Complex, sp Complex criteria sp Increased transferrin (TF) endocytosis strong GR00369-A Combinatorial effect with FBW7 26354767 995 995 shRNA abundance HCT116 [object Object] Gene Activity Ranking Profile (GARP) Difference of FBW7(-/-) and wt GARP scores that fell >3 SD away from the mean -0.01999999999999999 none GR00371-A-1 Nanog expression in absence of bFGF and TGFbeta 26232226 995 995 NANOG expression NANOG-GFP H1 hESC [object Object] Z-score >1,25 OR >1,5 [in at least two replicates] 0.34047237937 none Dharmacon GR00371-A-2 Nanog expression in presence of TGFbeta inhibitor 26232226 995 CDC25C NANOG expression NANOG-GFP H1 hESC [object Object] Z-score >1,25 OR >1,5 [in at least two replicates] 0.0648585745259 none Dharmacon GR00371-A-3 Nanog expression in presence of MEK inhibitor 26232226 995 995 NANOG expression NANOG-GFP H1 hESC [object Object] Z-score >1,25 OR >1,5 [in at least two replicates] 0.214810573676 none Dharmacon GR00371-A-4 Nanog expression in presence of PI3K inhibitor 26232226 995 995 NANOG expression NANOG-GFP H1 hESC [object Object] Z-score >1,25 OR >1,5 [in at least two replicates] -0.0746877624056 none Dharmacon GR00371-A-5 Nanog expression in presence of retinoic acid 26232226 995 995 NANOG expression NANOG-GFP H1 hESC [object Object] Z-score >1,25 OR >1,5 [in at least two replicates] -0.171978274942 none Dharmacon GR00376-A-1 Mitigators of SS1P-induced immunotoxicity 25713356 995 995 Viability KB cells [object Object] RSA P-value <0.001 0.314628614 none GR00376-A-2 Sensitizers of SS1P-induced immunotoxicity 25713356 995 995 Viability KB cells [object Object] RSA P-value <0.001 0.00333544 none GR00378-A Poliovirus vaccine production 26581994 995 Infection with Attenuated Poliovirus HEp-2C [object Object] Z-score >=3 -0.065841697 none GR00381-A-1 Regulation of mammary epithelial cell growth (1) 25572802 995 NM_001790 Viability 184-hTERT-L9 (mammary epithelial cells) [object Object] Percent growth < 25 % AND p-value < 0.05 105.639 none GR00386-A-1 NOD2 stimulation by MDP 25170077 995 995 Viability HEK293 stably expressing NOD2 [object Object] Percentage growth Decreased: <70, increased: >120 64.94514864656 Decreased viability GR00386-A-2 MDP-induced IL-8 secretion 25170077 995 995 IL-8 secretion HEK293 stably expressing NOD2 [object Object] Percent inhibition of IL-8 secretion Increased: <-300, Decreased: >60 70 Decreased IL-8 secretion GR00396-S Mammosphere formation and maintenance 24229464 995 NM_001790.3 shRNA quantification SUM149 p-value <0.01 0.08816055012934505 none GR00400-S-1 Combinatorial effect with vorinostat (1) 25977774 995 995 Caspase 3/7 activity HCT116 (Vorinostat resistant subclone) M-003228-02 Z-score >=5.13 0.36 none Reduced viability GR00400-S-2 Combinatorial effect with vorinostat (2) 25977774 995 995 Caspase 3/7 activity HCT116 (Vorinostat resistant subclone) D-003228-06 Z-score >=2.2 0.89 none GR00400-S-2 Combinatorial effect with vorinostat (2) 25977774 995 995 Caspase 3/7 activity HCT116 (Vorinostat resistant subclone) D-003228-07 Z-score >=2.2 0.86 none GR00400-S-2 Combinatorial effect with vorinostat (2) 25977774 995 995 Caspase 3/7 activity HCT116 (Vorinostat resistant subclone) D-003228-05 Z-score >=2.2 1.38 none Reduced viability GR00400-S-2 Combinatorial effect with vorinostat (2) 25977774 995 995 Caspase 3/7 activity HCT116 (Vorinostat resistant subclone) D-003228-08 Z-score >=2.2 1.25 none GR00402-S-1 Host restriction factor for the Mycobacterium tuberculosis infection to A549 cells (1) 995 995 The percentage of infected cells A549 SIR0003585 Z-score > 5 -2.1469757422744826 no effect 5 days post-infection GR00402-S-2 Host restriction factor for the Mycobacterium tuberculosis infection to A549 cells (2) 995 995 The percentage of infected cells A549 SIR0003585 Z-score > -3 -4.460505954803443 Decreased viability 5 days post-infection